Group 1 - Sanofi has filed its Form 20-F with the U.S. SEC and its "Document d'Enregistrement Universel" with the French AMF, which includes the Annual Financial Report [1] - These documents contain complete audited financial statements and are available on the company's website as well as the SEC and AMF websites [1] - A hard copy of the financial documents can be requested free of charge [1] Group 2 - Sanofi is an R&D driven, AI-powered biopharma company focused on improving lives and creating growth through innovative medicines and vaccines [2] - The company leverages its understanding of the immune system to develop treatments that benefit millions globally [2] - Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY [2]

Financial Transactions - Sanofi completed the Opella Transaction on April 30, 2025, generating a net cash inflow of €10.4 billion[604]. - Sanofi received an upfront payment of $825 million from the sale of global rights to Enjaymo, with potential milestone payments of up to $250 million based on sales[605]. - In 2024, Sanofi acquired Inhibrx for a net cash outflow of $2,035 million, adding SAR447537 to its rare disease pipeline[607]. - Sanofi entered into an agreement to acquire Dynavax and completed acquisitions of Vicebio, Blueprint, DR-0201, and Vigil[609]. Revenue Recognition and Accounting Policies - Revenue recognition policies are based on IFRS 15, with revenue recognized upon transfer of control over products to customers[611]. - Other revenues include royalty income and sales from non-Sanofi products, with significant contributions from VaxServe and manufacturing services[615]. - Sanofi's accounting policies for business combinations follow the acquisition method, measuring identifiable assets and liabilities at fair value[616]. - The company tests intangible assets for impairment based on future cash flows and market conditions, with significant assumptions involved[619]. Provisions and Expenses - Provisions for risks are recorded when there is a present obligation and a reliable estimate can be made of the outflow of resources[627]. - Provisions for restructuring costs are estimated based on past experience and management's knowledge, reflecting potential future obligations[630]. - R&D expenses increased by 6.1% to €7,842 million, representing 18.0% of net sales, driven by strategic prioritization in key therapeutic areas[663]. - Selling and general expenses rose by 3.9% to €9,543 million, accounting for 21.9% of net sales, reflecting improved operational efficiency[664]. Sales Performance - Net sales for 2025 reached €43,626 million, a 6.2% increase from €41,081 million in 2024, with a 9.9% rise at constant exchange rates (CER)[634]. - Dupixent generated net sales of €15,714 million, reflecting a 20.2% increase on a reported basis and a 25.2% increase at CER[638]. - ALTUVIIIO achieved net sales of €1,160 million, up 77.6% at CER, contributing to a total hemophilia A franchise sales of €1,435 million, a 42.6% increase at CER[641]. - Nexviazyme/Nexviadyme sales were €790 million, a 21.4% year-on-year increase, with total Pompe franchise sales reaching €1,309 million[642]. - New product launches contributed €5,721 million in sales, marking a 29.1% increase compared to the previous year[640]. Profitability Metrics - Gross profit margin improved to 77.2% in 2025 from 75.7% in 2024, despite an increase in research and development expenses to €7,842 million[634]. - Operating income decreased to €6,344 million, representing 14.5% of net sales, down from 17.7% in 2024[634]. - Net income for 2025 was €7,851 million, an increase of 39.5% from €5,618 million in 2024, with net income attributable to equity holders of Sanofi at €7,813 million[634]. - Basic earnings per share rose to €6.40 in 2025 from €4.44 in 2024, while diluted earnings per share increased to €6.37 from €4.43[634]. Cash Flow and Debt - Net cash provided by continuing operating activities was €10,561 million in 2025, up from €8,607 million in 2024[698]. - Net cash outflow from continuing investing activities was €12,849 million in 2025, compared to €4,298 million in 2024, primarily due to acquisitions[699]. - Total debt as of December 31, 2025, was €18,702 million, with net debt at €11,008 million, compared to €16,137 million and €8,772 million in 2024, respectively[691]. - The gearing ratio increased to 15.4% as of December 31, 2025, from 11.3% in 2024[692]. - Free cash flow for the year ended December 31, 2025, was €8,089 million, an increase from €5,955 million in 2024[705]. Asset and Equity Changes - Total assets decreased to €126,805 million as of December 31, 2025, from €132,798 million in 2024, a decline of €5,993 million[711]. - Total equity was €71,710 million as of December 31, 2025, down from €77,857 million in 2024[711]. - The increase in net debt was primarily due to cash outflows related to acquisitions exceeding €500 million per transaction and dividend payouts totaling €4,772 million[711]. - Cash inflow from the Opella transaction amounted to €10,443 million, contributing to the overall liquidity[711].

Clinical development has fundamentally changed, yet many supply chains have not. Nowadays making strategic adaptions to ensure secure patient access, control costs, and maintain high performance across the clinical supply chain is critical in ensuring a clinical trial’s success. Navigating the modern clinical trial supply chain requires technology and analytics to manage increasingly complex demands such as the cold storage of biologics and in handling cell and gene therapies (CGT). To enhance trial res ...

Positive Data From Inflammatory Bowel Disease StudyTeva and Sanofi SA (NASDAQ:SNY) released positive results on Tuesday from the RELIEVE UCCD long-term extension study of duvakitug, an investigational human monoclonal antibody targeting TL1A.The study demonstrated durable clinical efficacy maintained over 44 weeks in patients with ulcerative colitis and Crohn’s disease.The study involved 130 patients who initially responded to duvakitug in the induction phase, and both doses of duvakitug were well tolerated ...

Sanofi and Teva’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease In the RELIEVE UCCD LTE phase 2b study, duvakitug showed robust, durable efficacy for an additional 44 weeks in UC and CD patients who had responded after 14 weeks of induction Duvakitug was well tolerated and safety was consistent with the induction studyFindings reinforce the potential of duvakitug which is in ongoing phase 3 programs in UC and CD Paris and Pa ...

In the RELIEVE UCCD LTE phase 2b study, duvakitug showed robust, durable efficacy for an additional 44 weeks in UC and CD patients who had responded after 14 weeks of inductionDuvakitug was well tolerated and safety was consistent with the induction studyFindings reinforce the potential of duvakitug which is in ongoing phase 3 programs in UC and CD Teva will hold an investor call and live webcast today, Tuesday, February 17, 2026, at 8:00 a.m. ET to discuss these data. PARSIPPANY, N.J. and PARIS, Feb. 17, 2 ...

Market Overview - The Uterine Fibroid Market was valued at USD 5.26 Billion in 2025 and is projected to reach USD 9.43 Billion by 2033, growing at a CAGR of 7.63% from 2026 to 2033 [1][8]. Growth Drivers - The market is expanding due to the increased incidence of uterine fibroids among women of childbearing age, with approximately 70 to 80% of women experiencing fibroids by age 50 [2]. - Rising healthcare infrastructure in emerging markets and increased awareness regarding fibroid treatment options are also contributing to market growth [5]. Treatment Trends - There is a significant trend towards minimally invasive techniques for treating uterine fibroids, with adoption rates rising by over 60% in the past five years [4]. - Minimally invasive procedures are expected to grow at the fastest CAGR of 8.63% from 2026 to 2033, driven by advancements in technology and patient preference for less invasive options [11]. Market Segmentation - By Type: Submucosal Fibroids dominated with 36.24% in 2025, while Intramural Fibroids are expected to grow at the fastest CAGR of 8.20% from 2026 to 2033 [9][10]. - By Treatment Type: Surgical Procedures held 38.45% in 2025, with Minimally Invasive Procedures projected to grow at 8.63% CAGR [11]. - By Technology: Laparoscopic Surgery accounted for 36.58% in 2025, with MRI-Guided Focused Ultrasound expected to grow at 8.83% CAGR [12]. - By End-User: Hospitals & Clinics dominated with 47.49% in 2025, while Ambulatory Surgical Centers are expected to grow at 8.43% CAGR [13]. Regional Insights - The U.S. Uterine Fibroid Market was valued at USD 1.78 Billion in 2025 and is projected to reach USD 3.11 Billion by 2033, growing at a CAGR of 7.25% [14]. - North America is expected to hold a 45.32% market share in 2025, while Asia Pacific is anticipated to grow at the fastest CAGR from 2026 to 2033 [15]. Recent Developments - In January 2024, Pfizer Canada announced the availability of MYFEMBREE® for treating uterine fibroids and endometriosis [17]. - In September 2024, Theramex announced the first commercial sale of Yselty® in Germany, marking a new treatment option for women with moderate to severe symptoms of uterine fibroids [17].

Drugmaker Sanofi to expand India GCC, increase workforce to over 4,500 employees | ReutersSkip to main content[Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv]The logo of French drugmaker Sanofi is seen in Paris, France, January 9, 2026. REUTERS/Gonzalo Fuentes/File Photo [Purchase Licensing Rights, opens new tab]- Companies[Sanofi SA]Follow[Eli Lilly and Co]Follow[Merck KGaA]FollowShow more companiesFeb 16 (Reuters) - French drugmaker Sanofi [(SASY.PA), opens ...

Core Insights - A universal RSV immunization program using Beyfortus (nirsevimab) significantly reduced RSV-related hospitalizations in infants during their second RSV season after immunization in their first season [1][3] Group 1: Study Findings - The NIRSE-GAL study in Galicia, Spain, demonstrated a 94.4% coverage rate with 11,796 out of 12,492 eligible infants immunized [2] - There was an 85.9% reduction in RSV-related lower respiratory tract infection (LRTI) hospitalizations during the first season [2][6] - Infants who received Beyfortus during infancy experienced a 55.3% reduction in hospitalizations during their second RSV season [2] - The study also reported a 78.2% reduction in RSV-related rehospitalizations and a 62.4% reduction in LRTI rehospitalizations during the second season [4] Group 2: Implications for Public Health - The findings support the hypothesis that early protection against RSV-related lung damage may have lasting benefits on respiratory health [4] - The results provide compelling data to inform infant immunization strategies and economic evaluation models [3] Group 3: About Beyfortus - Beyfortus is designed to protect all infants during their first RSV season, including those born healthy at term or preterm, and those with health conditions [9] - It is a long-acting monoclonal antibody with an extended half-life of 71 days, administered as a single dose [10] - Over 11 million infants have been immunized with Beyfortus across more than 45 countries since its launch [11]

Core Insights - A universal RSV immunization program using Beyfortus (nirsevimab) significantly reduced RSV-related hospitalizations in infants during their second RSV season after immunization in their first season [1][3] Group 1: Study Findings - The NIRSE-GAL study in Galicia, Spain, demonstrated a 94.4% coverage rate among 11,796 infants out of 12,492 eligible, with an 85.9% reduction in RSV-related lower respiratory tract infection hospitalizations during the first season [2][6] - Infants who received Beyfortus during infancy experienced a 55.3% reduction in hospitalizations during their second RSV season [2] - The study also reported a 78.2% reduction in RSV-related rehospitalizations and a 62.4% reduction in lower respiratory tract infection rehospitalizations during the second season [4] Group 2: Implications for Public Health - The findings support the hypothesis that early protection against RSV-related lung damage may have lasting benefits on respiratory health, influencing infant immunization strategies and economic evaluation models [3][4] - The study's results provide compelling population-based data that can inform public health policies regarding RSV immunization [3] Group 3: About Beyfortus - Beyfortus is designed to protect all infants during their first RSV season, including those born healthy at term or preterm, and those with health conditions that make them vulnerable to RSV disease [9] - It is a long-acting monoclonal antibody with an extended half-life of 71 days, administered as a single dose to newborns and infants [10] - Over 11 million infants have been immunized with Beyfortus across more than 45 countries, demonstrating its widespread acceptance and use [11]